Can Enlicitide Keep LDL Down for Two Years?
New AHA 2026 reports suggest that the LDL drop from enlicitide, the first approved PCSK9 inhibitor that comes as a daily pill, lasts up to two years in people who stayed on treatment. A second analysis found similar reported LDL reductions whether people's calculated heart risk was low or high. Whether the pill prevents heart attacks and strokes is still being tested. The longer record comes from an uncontrolled study of adherent trial completers, which limits how broadly it applies. The firmer ground is the randomized evidence behind its July approval.
Enlicitide, sold as Lipfendra, became the first approved PCSK9 inhibitor you can swallow when the FDA approved it in July 2026 for adults with high LDL, including those with heterozygous familial hypercholesterolemia. Its power to lower LDL was established before approval. Two analyses at the American Heart Association's Scientific Sessions take on the next questions: does it work as well when your calculated heart risk is low, and does the effect last past a year? Both remain conference reports without full peer-reviewed publication; the detailed findings below come from the available conference summary because the original abstracts could not be independently checked.
What the randomized trials already settled
In CORALreef Lipids, a placebo-controlled trial, adding 20 mg of enlicitide a day to existing treatment lowered LDL by about 56% beyond placebo at 24 weeks. In CORALreef HeFH, 303 adults with heterozygous familial hypercholesterolemia had about a 59% placebo-adjusted drop. Most participants were already on statins, substantial lowering continued through a year, and apoB and non-HDL cholesterol fell by roughly half alongside LDL. Adverse-event rates overall were similar on the drug and placebo.
The routine is the practical cost of getting this drug class from a pill. The label calls for a morning dose on an empty stomach, swallowed whole with water, black coffee, or plain tea, and then at least 30 minutes before any food or other drinks. It also advises stopping the drug once pregnancy is recognized unless the benefit outweighs a possible risk to the fetus.
LDL fell across calculated risk levels
The available conference summary describes an analysis of 843 CORALreef Lipids participants at risk for a first major atherosclerotic cardiovascular event, grouped by their 10-year risk on the AHA's PREVENT calculator, the tool the 2026 ACC/AHA cholesterol guideline now uses for primary prevention. Reported placebo-corrected LDL reductions at 24 weeks were about 58%, 57%, and 58% in the borderline, intermediate, and high-risk groups. In every group, more people on the drug than on placebo got their LDL below 70 mg/dL.
Similar-looking numbers aren't the same as proof of an identical effect. The low-risk group was small, reported as 66 people (a figure that doesn't quite match the 8.2% of 843 given in the same report, and the summary doesn't explain the gap), so its estimate was imprecise. The low-risk label also needs careful reading, since about 59% of that group had diabetes and most participants across all groups were on moderate- or high-intensity statins. If you're a younger adult without diabetes who isn't on a statin, this analysis describes you only loosely.
Two years of data, from people who kept taking it
The second abstract is an interim look at the open-label extension, which offered enlicitide to people who finished one of three parent trials. LDL reportedly stayed well below its original baseline through week 104 of total treatment, though the plotted average reduction reportedly narrowed from roughly 65% early in treatment to about 50% at two years. Discontinuations because of adverse events were reported in 1.6%, and no drug-related serious adverse events were reported.
Entry required staying on parent-study treatment with at least 80% adherence, and there was no control group; prior treatment could have been enlicitide, placebo, or another drug. The available summary doesn't give the number measured at week 104, the way missing data were handled, or the safety reporting window. That narrowing could come from a fading drug effect, slipping adherence, or a change in who remained in the analysis, and the available data can't tell those apart. The low rate of stopping because of adverse events is reassuring within this selected group without being a reliable estimate for everyone who starts.
Where this leaves your LDL decision
| Evidence stage | What it shows | What remains uncertain |
|---|---|---|
| Randomized phase 3 trials | Substantial additional LDL lowering through one year | Whether enlicitide prevents heart attacks or strokes |
| AHA risk-subgroup analysis | Similar reported LDL reductions across risk levels | Whether risk changes the response; the formal interaction test is unavailable |
| AHA open-label extension | Substantial reported LDL lowering up to two years | How well durability and tolerability extend to everyone starting treatment |
Your risk affects how much further LDL lowering is likely to be worth to you in prevented events. The 2026 guideline says cholesterol treatment should be considered at intermediate risk and can be considered at borderline risk, after a discussion with a clinician. A meta-analysis of randomized trials found that further LDL lowering reduced major vascular events across starting LDL levels and in people with and without diabetes, with benefits also seen at lower baseline cardiovascular risk, which supports considering targets below guideline cutoffs when the expected benefit justifies treatment.
That makes enlicitide a live option if your LDL is still above where you and your clinician want it despite a statin, especially if you'd rather take a pill than an injection and can manage the morning routine. Starting it takes a prescription. You can check your response directly: the label allows an LDL check as early as four weeks, and repeating LDL and apoB over time shows whether your response matches the trials.
None of these enlicitide studies established that it prevents heart attacks or strokes. Injectable PCSK9 antibodies lowered cardiovascular events in large outcome trials of people with atherosclerotic cardiovascular disease, and enlicitide lowers LDL by a similar amount, but its own outcome trial is still running, so the event benefit is an expectation built on LDL lowering. These abstracts alone also give no reason to replace an injection or another treatment that's already getting your LDL where you want it, or to start the pill only because it worked in a small low-risk subgroup. Full publication would allow closer assessment of the risk-level and durability findings, and larger studies in lower-risk adults without diabetes would show how far they reach.